Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) posted a decline in its consolidated net profit to 21.5 billion Indian rupees in the fiscal fourth quarter ended March 31, against 26.5 billion rupees a year ago.
Earnings per share contracted to 9.0 rupees compared with the year-ago figure of 11.1 rupees, according to a Thursday filing to the Indian stock exchanges by the pharmaceutical company.
Revenue from operations in fiscal Q4, however, increased to 129.6 billion rupees from 119.8 billion rupees a year earlier.
The company's board declared a final dividend of 5.50 rupees per equity share of 1 rupee each.
Sun Pharma's shares were down nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.